of 47
7/27/2019 Pharmacology Chapter 3
1/47
1
Chapter 3Anti-inflammatoryMedications
7/27/2019 Pharmacology Chapter 3
2/47
2
NSAIDs The use of NSAIDs for the treatment of
sports-related injuries, as well as other
maladies, (namely osteoarthritis)continues to rise.
In 2001, sales of NSAID prescriptions
accounted for $10.9 billion in the UnitedStates.
7/27/2019 Pharmacology Chapter 3
3/47
7/27/2019 Pharmacology Chapter 3
4/47
7/27/2019 Pharmacology Chapter 3
5/47
5
The InflammatoryResponse The acute inflammatory cascade is set
into motion by the initial tissue insult.
Grossly, acute inflammation isrecognized by the classic and familiarsigns of pain (dolor), heat (calor),
erythema (rubor), swelling (tumor), andloss of function (functio laesa).
7/27/2019 Pharmacology Chapter 3
6/47
6
Figure 3-1: TheInflammatory Response
7/27/2019 Pharmacology Chapter 3
7/47
7
Inflammatory Response(cont.) Following a short period of
vasoconstriction - cellular injury signals
the release of chemical mediators, suchas histamine, serotonin, anaphylatoxins,bradykinin, thromboxane, leukotrienes,and prostaglandins.
7/27/2019 Pharmacology Chapter 3
8/47
8
Box 3-2 page 36 Major actions of the Eicosanoids
Prostaglandins
Thromboxane
Leukotrienes
7/27/2019 Pharmacology Chapter 3
9/47
9
Anti-inflammatoryMedications Aspirin (acetylsalicylic acid) - a derivative
of salicylic acid.
Salicylic acid, in turn, was created fromsalicin, which is found in the bark of willowtrees.
Aspirin was first synthesized by a BayerCompany chemist in the late 19th century.
It proved to be far less of a gastric irritantthan salicylic acid and was introduced to the
marketplace in the spring of 1899.
7/27/2019 Pharmacology Chapter 3
10/47
10
In 1971, Sir John Vane discovered that the
aspirin molecule transfers a functionalgroup onto the cyclooxygenase enzyme.Until this time the actual mechanism ofaction for aspirin was unknown.
7/27/2019 Pharmacology Chapter 3
11/47
11
Cyclooxygenase Enzyme(COX)
This enzyme is irreversibly inhibited andunable to bind arachidonic acid, therefore,the enzyme can no longer convertarachidonic acid to prostaglandins andthromboxane.
The Leukotriene pathway, however, isunaffected
7/27/2019 Pharmacology Chapter 3
12/47
12
Effects of Aspirin Analgesic
Antipyretic
Anticoagulant
Anti-inflammatory
7/27/2019 Pharmacology Chapter 3
13/47
13
Effects of Aspirin 3000 6000 mg per day for anti-
inflammatory action; a series of chemical
events results from the blockage ofcyclooxygenase
325 mg aspirin = 12 to 18 aspirin per dayto reach an anti-inflammatory effect
7/27/2019 Pharmacology Chapter 3
14/47
14
Effects of Aspirin The decrease in prostaglandin production
leads to a corresponding reduction in
inflammation and edema.
7/27/2019 Pharmacology Chapter 3
15/47
15
Effects of Aspirin Blocks prostaglandin production, even
the cytoprotection.
In the GI tract, aspirin can cause gastricupset, bleeding, and even ulcers.
Various studies have shown GI disturbance
incidence of anywhere from 2 percent to 40percent.
7/27/2019 Pharmacology Chapter 3
16/47
16
Effects of Aspirin The mechanism of gastric irritation
appears related to the direct effect of
aspirin upon the lining of the stomach.
Mild gastrointestinal upset can often be
avoided if aspirin is taken with a meal,due to the "buffering" action of the food.
7/27/2019 Pharmacology Chapter 3
17/47
17
Effects of Aspirin Aspirin use may also result in
complications, such as prolonged
bleeding and tinnitus. Decreased platelet function lasts from 4 to 6
days (used for blood thinning in heartpatients).
Tinnitus may be an indication of aspirintoxicity.
7/27/2019 Pharmacology Chapter 3
18/47
18
Reyes Syndrome Reyes syndrome is a rare and potentially
devastating, acute illness that usually
strikes children following a viral infectionwhen they are given aspirin to lowerfever.
This syndrome is now suspected in teensand young adults with viral infections whotake aspirin.
7/27/2019 Pharmacology Chapter 3
19/47
19
Table 3-1: The FiveClinical Stages of ReyesSyndrome
7/27/2019 Pharmacology Chapter 3
20/47
20
Aspirin Sensitive Asthma Upon exposure to even small quantities
of aspirin, those affected may developnasal congestion and acute, often severe
bronchospasm. There is an almost universal cross-
reactivity with other NSAIDs.
Patients can be desensitized over timewith daily administration of aspirin andcross-tolerance to other NSAIDs usuallyoccurs.
7/27/2019 Pharmacology Chapter 3
21/47
21
Acetaminophen Acetaminophen (Tylenol) is not an anti-
inflammatory agent, it has antipyretic and
analgesic properties. Will be discussed with the analgesics
(Chapter 10).
7/27/2019 Pharmacology Chapter 3
22/47
22
NSAIDs COX-2 Inhibitors
Primarily induced at sites of inflammation
COX-2 inhibitor could block the production ofproinflammatory prostaglandins withoutinterfering with gastric protection or plateletactivity
Research is controversial and the drugs areexpensive
7/27/2019 Pharmacology Chapter 3
23/47
23
Overview of SelectedNSAIDs Box 3-4 Page 42 Factors to Consider in
Choosing an NSAID
Age of Patient Duration of Treatment
Time of Onset
Compliance
Other Medications General Health of Patient
Cost of Treatment
7/27/2019 Pharmacology Chapter 3
24/47
24
Ibuprofen Advil, Motrin, Nuprin
Most frequently used NSAID
Introduced to the OTC market in 1985, itis available in 200 to 800 mg tablets byprescription, and 200 mg tablets OTC
Frequently used as an antipyretic inadults and children, as its longer durationof action makes it a popular alternative toacetaminophen
7/27/2019 Pharmacology Chapter 3
25/47
25
Ibuprofen Peak plasma levels are achieved within
15 to 30 minutes of ingestion
Rapid onset of action can be quitebeneficial for quick relief of pain
Half-life of about 2 hours, it must be
taken every 6 to 8 hours to maintaineffect
An anti-inflammatory regimen requires
2400 3200 mg daily
7/27/2019 Pharmacology Chapter 3
26/47
26
Ibuprofen Taken in three separate doses, allowing
it to be taken at meal times, lessening the
likelihood of gastric irritation. Sufficient analgesia should be achieved
by daily dosages of less than 2400 mgper day.
Approximately 10 percent to 15 percentof individuals must discontinue usesecondary to gastrointestinal symptoms.
7/27/2019 Pharmacology Chapter 3
27/47
27
Naproxen Naprosyn, Aleve.
Chemically similar to ibuprofen.
Naproxen is available as the OTC preparationAleve, and asAnaproxby prescription.
Due to naproxen's long half-life (approximately12 hours), the daily recommended dosage of
750 1000 mg can be taken on a twice dailyschedule, reducing gastric upset due to onlytwo exposures and improving compliance.
7/27/2019 Pharmacology Chapter 3
28/47
28
Naproxen Peak plasma levels are achieved within 2
to 4 hours
Incidence of upper gastrointestinalbleeding in OTC use is double that ofOTC ibuprofen
7/27/2019 Pharmacology Chapter 3
29/47
29
Indomethacin Indocin.
Although particularly effective in maladiessuch as rheumatoid arthritis, ankylosing
spondylitis, and gout, indomethacin istypically not recommended for use as asimple analgesic or antipyretic due topotentially severe side-effects.
Up to half of those using indomethacinmay experience some side-effects andalmost one-third will discontinue use.
7/27/2019 Pharmacology Chapter 3
30/47
30
Indomethacin Common side-effects include
gastrointestinal symptoms (ulceration,nausea, abdominal pain) and headaches(15 percent to 25 percent of patients).
Peak concentrations can be achieved in 1to 2 hours (in fasting subjects, onset isdelayed by food intake).
7/27/2019 Pharmacology Chapter 3
31/47
31
Indomethacin A half-life of about 2.5 hours. Daily dosage ranges from 75 mg 100
mg taken in two to three doses. Indomethacins use has declined as newer
agents with a lower side-effect profile haveemerged.
7/27/2019 Pharmacology Chapter 3
32/47
32
Nabumetone (Relafen) Only nonacid NSAID currently available
Once-a-day treatment; half-life is 24
hours
7/27/2019 Pharmacology Chapter 3
33/47
33
Rofecoxib Vioxx
One of only three potent and highly
selective COX-2 inhibitors available. It does not inhibit COX-1 and has no
effect on platelet function.
It is FDA approved for the treatment ofosteoarthritis, dysmenorrhea, and acutepain.
7/27/2019 Pharmacology Chapter 3
34/47
34
Rofecoxib Dosages range from 12.5 mg 50 mg. It
is administered once daily given its
nearly 17-hour half-life. Long-term toxic effects, including
gastrointestinal and renal effects, are not
yet known given the drugs relativelyrecent introduction.
7/27/2019 Pharmacology Chapter 3
35/47
35
Celecoxib Celebrex
COX-2 inhibitor
200 mg tablets Peak Plasma levels = 3 hours
Half-life (approximate-effective) = 11 hours
Problems include: Liver and kidneys
Heart ?
7/27/2019 Pharmacology Chapter 3
36/47
36
Ketorolac Toradol.
Not typically employed for its anti-
inflammatory properties. It is the only NSAID available for
intramuscular or intravenous injection as
well as oral administration.
7/27/2019 Pharmacology Chapter 3
37/47
37
Ketorolac Although it also has anti-inflammatory
and antipyretic properties, it is mostcommonly marketed and used as an
analgesic, particularly in postoperativepatients.
As an analgesic, ketorolac offers great
promise as it avoids the most commonshortcomings of opioids, i.e., tolerance,withdrawal effects, and respiratory
depression.
7/27/2019 Pharmacology Chapter 3
38/47
38
Ketorolac Interestingly, Tokish et al (1992) recently
reported that 28 of 30 National Football
League team medical staffs commonlyuse ketorolac intramuscular injections ongame days for pain relief.
Due to high risk of renal effects, durationof ketorolac treatment is typically held toless than 5 days.
7/27/2019 Pharmacology Chapter 3
39/47
39
NSAID Indications
7/27/2019 Pharmacology Chapter 3
40/47
40
NSAID Adverse Effects
7/27/2019 Pharmacology Chapter 3
41/47
41
NSAID Use
7/27/2019 Pharmacology Chapter 3
42/47
42
Drug-Drug Interactions
7/27/2019 Pharmacology Chapter 3
43/47
43
Glucocorticosteroids Animal studies demonstrate:
Potent anti-inflammatory actions ofglucocorticosteroids and their subsequenteffects upon healing
Glucocorticosteroids induced an early,transient recovery of the force-generatingcapacity of the effected muscle
Long-term findings revealed irreversibledamage to the healing muscle, includingatrophy and diminished force-generatingcapacity
7/27/2019 Pharmacology Chapter 3
44/47
44
Actions of Corticosteroids
7/27/2019 Pharmacology Chapter 3
45/47
45
Corticosteroids in SportsMedicine Stanley and Weaver (1989) state that
inconsistency in the studies onglucocorticosteroid use does not lendadequate support or direction to thesports medicine clinician in their use.
Extremely powerful anti-inflammatory
medications but no good research todemonstrate their effectiveness inactivity-related injury.
7/27/2019 Pharmacology Chapter 3
46/47
46
Box 3-7: Most CommonIndications for InjectableCorticosteroids
7/27/2019 Pharmacology Chapter 3
47/47
47
Box 3-8: PotentialComplications ofInjectable Corticosteroids